At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 196 enrolled
Drug / intervention
dapagliflozin and saxagliptindrug
Likely dose
dapagliflozin and saxagliptin 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Multicenter, Phase -IV Study to Assess the Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Indian Type 2 Diabetes Mellitus (T2D) Patients
In Brief
A Phase 4 clinical trial evaluating dapagliflozin and saxagliptin for Type 2 Diabetes Mellitus. Completed, enrolled 196 participants across 9 sites.
Detailed Summary
A prospective, multicenter, phase -IV study to assess the safety of fixed dose combination of dapagliflozin and saxagliptin in Indian Type 2 Diabetes Mellitus (T2D) patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesIndia
Collaborators--
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartApr 2021
Primary CompletionMar 2023
TodayJul 2026
First PostedJun 24, 2020
Enrollment StartApr 7, 2021
Primary CompletionMar 14, 2023
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 6.0 years ago
Interventions
dapagliflozin and saxagliptindrug
Combination of dapagliflozin and saxagliptin tablet once daily fixed dose combination of Dapa/Saxa 10 mg/5 mg administered orally